Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VIA Pharmaceuticals said that non-profit organization Genome Quebec will provide part of the funding needed for a pharmacogenomics sub-study on VIA's atherosclerosis drug candidate.
Subscribe to our email newsletter
The primary focus of the project will be to develop a 5 Lipoxygenase (5-LO) genotyping panel for VIA-2291, VIA’s lead candidate for cardiovascular disease, as well as a next-generation all-inclusive ADME/Tox panel. Additionally, the project includes development of genotyping panels broadly applicable to future clinical trials.
Funding of the program will be approximately $5 million at current US and Canadian exchange rates, with VIA providing approximately $2.4 million of this funding for expenditures planned in its acute coronary syndrome (ACS) clinical trial, and approximately $200,000 for costs related to the pharmacogenomics sub-study. Genome Quebec and other companies will be providing the balance of the co-funding.
Lawrence Cohen, CEO, said: “We believe that this sub-study will generate important information on the pharmacogenomics of our study patients, and will provide additional insight into the role we believe VIA-2291 will play in reducing vascular inflammation in ACS patients with atherosclerosis.”